Ishihara M, Tyrrell D J, Stauber G B, Brown S, Cousens L S, Stack R J
Glycomed Incorporated, Alameda, California 94501.
J Biol Chem. 1993 Mar 5;268(7):4675-83.
Homogeneously sized, heparin-derived oligosaccharides were prepared from heparin following partial depolymerization with nitrous acid, reduction with sodium borohydride, and fractionation by gel permeation chromatography. The resulting pools of di-, tetra-, hexa-, octa-, and decasaccharides were sequentially applied to an affinity column of human recombinant basic fibroblast growth factor (bFGF) covalently attached to Sepharose 4B and further fractionated into subpools based on their elution from this column in response to gradients of sodium chloride. In general, pools of smaller heparin-derived oligosaccharides required relatively lower salt concentration for complete elution, and pools of larger oligosaccharides required higher salt concentration. The homogeneously sized pools and affinity-fractionated subpools of heparin-derived oligosaccharides were quantitatively assessed as inhibitors or enhancers of specific bFGF-mediated biological activities in five separate assay systems as follows: assay 1, to compete with human lymphoblastoid cells expressing syndecan (RO-12 UC cells) for binding to bFGF-coated wells (Ishihara, M., Tyrrell, D.J., Kiefer, M.C., Barr, P.J., and Swiedler, S.J. (1992) Anal. Biochem. 202, 310-315); assay 2, to inhibit 125I-bFGF binding to "low affinity sites" of adrenocortical endothelial (ACE) cells; assay 3, to inhibit bFGF-induced proliferation of ACE cells; assay 4, to support mitogenic activity of bFGF in a growth stimulation assay of chlorate-treated ACE cells; and assay 5, to enhance the in vitro interaction between 125I-bFGF and the recombinant extra-cellular domain of FGF high affinity receptor. The data derived from the five assay systems demonstrated that heparin-derived hexa- and octasaccharides inhibited the interaction between cell surface heparan sulfate proteoglycan and bFGF (assays 1 and 2) and bFGF-induced proliferation of ACE cells (assay 3) but were unable to enhance the binding of bFGF to its high affinity receptor in vitro (assay 5) or to support bFGF-induced mitogenesis in ACE cells (assay 4). These two activities required at least a decasaccharide with high affinity for bFGF.
通过亚硝酸部分解聚、硼氢化钠还原以及凝胶渗透色谱分级分离,从肝素制备出大小均一的肝素衍生寡糖。将得到的二糖、四糖、六糖、八糖和十糖组分依次应用于共价连接到琼脂糖4B上的人重组碱性成纤维细胞生长因子(bFGF)亲和柱,并根据它们在氯化钠梯度作用下从该柱上的洗脱情况进一步分级为亚组分。一般来说,较小的肝素衍生寡糖组分需要相对较低的盐浓度才能完全洗脱,而较大的寡糖组分需要较高的盐浓度。对大小均一的肝素衍生寡糖组分和亲和分级的亚组分在以下五个独立的测定系统中作为特定bFGF介导的生物学活性的抑制剂或增强剂进行了定量评估:测定1,与人表达syndecan的淋巴母细胞(RO - 12 UC细胞)竞争结合包被有bFGF的孔(石原,M.,泰勒尔,D.J.,基弗,M.C.,巴尔,P.J.,和斯维德勒,S.J.(1992年)分析生物化学202,310 - 315);测定2,抑制125I - bFGF与肾上腺皮质内皮(ACE)细胞“低亲和力位点”的结合;测定3,抑制bFGF诱导的ACE细胞增殖;测定4,在氯酸盐处理的ACE细胞的生长刺激测定中支持bFGF的促有丝分裂活性;测定5,增强125I - bFGF与FGF高亲和力受体的重组细胞外结构域之间的体外相互作用。来自这五个测定系统的数据表明,肝素衍生的六糖和八糖抑制细胞表面硫酸乙酰肝素蛋白聚糖与bFGF之间的相互作用(测定1和2)以及bFGF诱导的ACE细胞增殖(测定3),但不能增强bFGF在体外与它的高亲和力受体的结合(测定5)或支持bFGF诱导的ACE细胞有丝分裂(测定4)。这两种活性至少需要对bFGF具有高亲和力的十糖。